Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Cellectis

- PMLiVE

Japanese approvals for GSK, AZ and Bayer

MHLW gives Nucala, Tagrisso and Xofigo the green light

AstraZeneca AZ

AZ’s Brilinta disappoints in stroke trial

Antiplatelet drug fails to demonstrate significant benefit in ischaemic stroke

- PMLiVE

NICE promises UK to lead Europe for cancer drug approvals

But industry says running the new CDF will present NICE with a ‘hugely challenging’ task

- PMLiVE

Focus on multiple myeloma treatment: Witnessing a transformation

Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.

Blue Latitude Health

AZ and Roche fund PatientsLikeMe cancer patient outcomes study

The online patient network's cancer experience research will also involve M2Gen

AstraZeneca AZ global R&D corporate HQ

AZ’s influenza drug fast tracked in US

FDA expedites MEDI8852 to help meet an acute need for new flu treatments

AstraZeneca AZ global R&D corporate HQ

AZ offloads more products in slimming drive

Will invest Moventig, Plendil and Imdur proceeds in its R&D pipeline

AstraZeneca AZ global R&D corporate HQ

AZ’s tremelimumab fails mesothelioma trial

FDA-designated breakthrough therapy did not demonstrate increase in overall survival

Bristol Myers Squibb logo

Opdivo backed for two new uses by CHMP

Recommended for additional European approvals in kidney cancer and NSCLC

- PMLiVE

New UK Cancer Drugs Fund takes shape

NICE to manage access to cancer treatments from 1 July

Eli Lilly HQ

Lilly wins European approval for lung cancer drug Portrazza

First biologic licenced in EU as a first-line treatment for adults with NSCLC

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links